TOP HEADLINES

Featured Story

FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine

Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.

Cancer vaccine partners J&J, Aduro add $817M pact

Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.

Sanofi, Selecta join hands in diabetes vaccine push

Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.

Bexsero could be cost-effective for England, model says--but not at Novartis' price

What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.

Sanofi takes rotavirus vax into Phase III with eye on Indian market

India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.

MORE NEWS

From Our Sister Sites

FiercePharma

Moncef Slaoui With a three-part, multi-billion dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management...

FierceDrugDelivery

Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.